Genetics and molecular epidemiology of multiple myeloma: The rationale for the IMMEnSE consortium (review)

International Journal of Oncology

Volumn 40, Issue 3, 2012, Pages 625-638

  Martino, Alessandro ^a   Sainz, Juan ^b,c   Buda, Gabriele ^d   Jamroziak, Krzysztof ^e   Reis, Rui Manuel ^f,k   García Sanz, Ramón ^g   Jurado, Manuel ^b,c   Ríos, Rafael ^b,c   Szemraj Rogucka, Zofia ^e   Marques, Herlander ^f   Lesueur, Fabienne ^h   Moreno, Victor ⁱ   Orciuolo, Enrico ^d   Gemignani, Federica ^d   Landi, Stefano ^d   Rossi, Anna Maria ^d   Dumontet, Charles ^j   Petrini, Mario ^d   Campa, Daniele ^a   Canzian, Federico ^a  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF GRANADA   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d UNIVERSITY OF PISA   (Italy)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f UNIVERSITY OF MINHO   (Portugal)

^g Centro de Investigacion del Cancer   (Spain)

^h INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

^j CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^k BARRETOS CANCER HOSPITAL   (Brazil)

more..

Author keywords

Genetic susceptibility; IMMEnSE consortium; Multiple myeloma; Pharmacogenetics; SNPs

Indexed keywords

ALPHA INTERFERON; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; PARAPROTEIN;

CANCER INCIDENCE; CANCER SUSCEPTIBILITY; CELL CYCLE; CELL INFILTRATION; DNA REPAIR; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HUMAN; IMMUNOGLOBULIN PRODUCTION; MOLECULAR EPIDEMIOLOGY; MULTIPLE MYELOMA; MYELOMA CELL; OVERALL SURVIVAL; PHENOTYPE; PLASMA CELL; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MOLECULAR EPIDEMIOLOGY; MULTIPLE MYELOMA; PHARMACOGENETICS; RISK FACTORS;

EID: 84857165192     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2011.1284     Document Type: Review

References (148)

1. International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 121: 749-757, 2003.
2. Raab MS, Podar K, Breitkreutz I, Richardson PG and Anderson KC: Multiple myeloma. Lancet 374: 324-339, 2009.
3. Ferlay J, Parkin DM and Steliarova-Foucher E: Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 46: 765-781, 2010.
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
5. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
6. Avet-Loiseau H, Li C, Magrangeas F, et al: Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol 27: 4585-4590, 2009.
7. Parkin DM and Muir CS: Cancer incidence in five continents. Comparability and quality of data. IARC Sci Publ, pp45-173, 1992.
8. Alexander DD, Mink PJ, Adami HO, et al: Multiple myeloma: a review of the epidemiologic literature. Int J Cancer 120 (Suppl 12): S40-S61, 2007.
9. Altekruse SF, Kosary CL, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2007. National Cancer Institute, Bethesda, 2010.
10. Davey Smith G, Neaton JD, Wentworth D, Stamler R and Stamler J: Mortality differences between black and white men in the USA: contribution of income and other risk factors among men screened for the MRFIT. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Lancet 351: 934-939, 1998. (Pubitemid 28138466)
11. Ries LAG, Eisner MP, Kosary CL, et al (eds): SEER Cancer Statistics Review, 1975-2002. National Cancer Institute, Bethesda, 2005.
12. Bergsagel D: The incidence and epidemiology of plasma cell neoplasms. Stem Cells 13 (Suppl 2): S1-S9, 1995.
13. Ludwig H, Bolejack V, Crowley J, et al: Survival and years of life lost in different age cohorts of patients with multiple myeloma. J Clin Oncol 28: 1599-1605, 2010.
14. Ludwig H, Durie BG, Bolejack V, et al: Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival: an analysis of 10549 patients from the International Myeloma Working Group. Blood 111: 4039-4047, 2008.
15. Landgren O, Kyle RA, Pfeiffer RM, et al: Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113: 5412-5417, 2009.
16. Weiss BM, Abadie J, Verma P, Howard RS and Kuehl WM: A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113: 5418-5422, 2009.
17. Kyle RA, Therneau TM, Rajkumar SV, et al: Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 354: 1362-1369, 2006.
18. Kuehl WM and Bergsagel PL: Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2: 175-187, 2002. (Pubitemid 37328787)
19. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF and Melton LJ III: Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clin Proc 79: 859-866, 2004. (Pubitemid 38879951)
20. Kyle RA and Greipp PR: Smoldering multiple myeloma. N Engl J Med 302: 1347-1349, 1980. (Pubitemid 10117727)
21. Kyle RA and Rajkumar SV: Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 23: 3-9, 2009.
22. Martinez-Lopez J, Blade J, Mateos MV, et al: Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. Blood 118: 529-534, 2011.
23. Rajkumar SV: Treatment of myeloma: cure vs control. Mayo Clin Proc 83: 1142-1145, 2008.
24. Gay F, Larocca A, Wijermans P, et al: Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. Blood 117: 3025-3031, 2011.
25. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341: 1565-1571, 1999.
26. Richardson PG, Barlogie B, Berenson J, et al: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2003. (Pubitemid 36741588)
27. Rajkumar SV, Hayman SR, Lacy MQ, et al: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 106: 4050-4053, 2005. (Pubitemid 41775908)
28. Rajkumar SV, Richardson PG, Hideshima T and Anderson KC: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23: 630-639, 2005. (Pubitemid 46224241)
29. Quach H, Ritchie D, Stewart AK, et al: Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia 24: 22-32, 2010.
30. Palumbo A and Anderson K: Multiple myeloma. N Engl J Med 364: 1046-1060, 2011.
31. Ferlay J, Bray F, Sankila R and Parkin DM: EUCAN: Cancer Incidence Mortality and Prevalence in the European Union 1998. IARC Press, Lyon, 1999.
32. Larsson SC and Wolk A: Body mass index and risk of multiple myeloma: a meta-analysis. Int J Cancer 121: 2512-2516, 2007. (Pubitemid 350022422)
33. Wallin A and Larsson SC: Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies. Eur J Cancer 47: 1606-1615, 2011.
34. Fritschi L, Ambrosini GL, Kliewer EV, Johnson KC and Canadian Cancer Registries Epidemiologic Research Group: Dietary fish intake and risk of leukaemia, multiple myeloma, and non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 13: 532-537, 2004.
35. Hosgood HD III, Baris D, Zahm SH, Zheng T and Cross AJ: Diet and risk of multiple myeloma in Connecticut women. Cancer Causes Control 18: 1065-1076, 2007. (Pubitemid 47498157)
36. Pekmezovic T, Vlajinac H, Adanja B, et al: Dietary factors and multiple myeloma. Case-control study in Belgrade. IARC Sci Publ 156: 231-232, 2002.
37. Eriksson M: Rheumatoid arthritis as a risk factor for multiple myeloma: a case-control study. Eur J Cancer 29A: 259-263, 1993.
38. Matteson EL, Hickey AR, Maguire L, Tilson HH and Urowitz MB: Occurrence of neoplasia in patients with rheumatoid arthritis enrolled in a DMARD Registry. Rheumatoid Arthritis Azathioprine Registry Steering Committee. J Rheumatol 18: 809-814, 1991.
39. Dal Maso L and Franceschi S: Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol 4: 110-119, 2003. (Pubitemid 36193171)
40. Cheung MC, Pantanowitz L and Dezube BJ: AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist 10: 412-426, 2005. (Pubitemid 40993569)
41. Simard EP, Pfeiffer RM and Engels EA: Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 117: 1089-1096, 2011.
42. Perrotta C, Staines A and Cocco P: Multiple myeloma and farming. A systematic review of 30 years of research. Where next? J Occup Med Toxicol 3: 27, 2008.
43. Khuder SA and Mutgi AB: Meta-analyses of multiple myeloma and farming. Am J Ind Med 32: 510-516, 1997. (Pubitemid 27419253)
44. Gold LS, Milliken K, Stewart P, et al: Occupation and multiple myeloma: an occupation and industry analysis. Am J Ind Med 53: 768-779, 2010.
45. Lope V, Perez-Gomez B, Aragones N, et al: Occupation, exposure to chemicals, sensitizing agents, and risk of multiple myeloma in Sweden. Cancer Epidemiol Biomarkers Prev 17: 3123-3127, 2008.
46. Orsi L, Delabre L, Monnereau A, et al: Occupational exposure to pesticides and lymphoid neoplasms among men: results of a French case-control study. Occup Environ Med 66: 291-298, 2009.
47. Brown LM, Burmeister LF, Everett GD and Blair A: Pesticide exposures and multiple myeloma in Iowa men. Cancer Causes Control 4: 153-156, 1993. (Pubitemid 23077022)
48. Baris D, Silverman DT, Brown LM, et al: Occupation, pesticide exposure and risk of multiple myeloma. Scand J Work Environ Health 30: 215-222, 2004. (Pubitemid 38931180)
49. Semenciw RM, Morrison HI, Riedel D, Wilkins K, Ritter L and Mao Y: Multiple myeloma mortality and agricultural practices in the Prairie provinces of Canada. J Occup Med 35: 557-561, 1993. (Pubitemid 23170083)
50. Bond GG, Bodner KM, Olsen GW and Cook RR: Mortality among workers engaged in the development or manufacture of styrene-based products - an update. Scand J Work Environ Health 18: 145-154, 1992. (Pubitemid 23363436)
51. Grodstein F, Hennekens CH, Colditz GA, Hunter DJ and Stampfer MJ: A prospective study of permanent hair dye use and hematopoietic cancer. J Natl Cancer Inst 86: 1466-1470, 1994. (Pubitemid 24317589)
52. Massoudi BL, Talbott EO, Day RD, Swerdlow SH, Marsh GM and Kuller LH: A case-control study of hematopoietic and lymphoid neoplasms: the role of work in the chemical industry. Am J Ind Med 31: 21-27, 1997. (Pubitemid 27020090)
53. Thun MJ, Altekruse SF, Namboodiri MM, Calle EE, Myers DG and Heath CW Jr: Hair dye use and risk of fatal cancers in U.S. women. J Natl Cancer Inst 86: 210-215, 1994. (Pubitemid 24042262)
54. Torchio P, Lepore AR, Corrao G, et al: Mortality study on a cohort of Italian licensed pesticide users. Sci Total Environ 149: 183-191, 1994. (Pubitemid 24173322)
55. Viel JF and Richardson ST: Lymphoma, multiple myeloma and leukaemia among French farmers in relation to pesticide exposure. Soc Sci Med 37: 771-777, 1993.
56. Mills PK, Newell GR, Beeson WL, Fraser GE and Phillips RL: History of cigarette smoking and risk of leukemia and myeloma: results from the Adventist health study. J Natl Cancer Inst 82: 1832-1836, 1990.
57. Brown LM, Gibson R, Burmeister LF, Schuman LM, Everett GD and Blair A: Alcohol consumption and risk of leukemia, non-Hodgkin's lymphoma, and multiple myeloma. Leuk Res 16: 979-984, 1992.
58. Ichimaru M, Ishimaru T, Mikami M and Matsunaga M: Multiple myeloma among atomic bomb survivors in Hiroshima and Nagasaki, 1950-76: relationship to radiation dose absorbed by marrow. J Natl Cancer Inst 69: 323-328, 1982. (Pubitemid 12018579)
59. Stagnaro E, Ramazzotti V, Crosignani P, et al: Smoking and hematolymphopoietic malignancies. Cancer Causes Control 12: 325-334, 2001. (Pubitemid 32553625)
60. Brown LM, Pottern LM, Silverman DT, et al: Multiple myeloma among Blacks and Whites in the United States: role of cigarettes and alcoholic beverages. Cancer Causes Control 8: 610-614, 1997. (Pubitemid 27330493)
61. Preston DL, Kusumi S, Tomonaga M, et al: Cancer incidence in atomic bomb survivors. Part III. Leukemia, lymphoma and multiple myeloma, 1950-1987. Radiat Res 137: S68-S97, 1994. (Pubitemid 24060247)
62. Judson IR, Wiltshaw E and Newland AC: Multiple myeloma in a pair of monozygotic twins: the first reported case. Br J Haematol 60: 551-554, 1985. (Pubitemid 15032642)
63. Landgren O, Linet MS, McMaster ML, Gridley G, Hemminki K and Goldin LR: Familial characteristics of autoimmune and hematologic disorders in 8,406 multiple myeloma patients: a population-based case-control study. Int J Cancer 118: 3095-3098, 2006.
64. Eriksson M and Hallberg B: Familial occurrence of hematologic malignancies and other diseases in multiple myeloma: a case-control study. Cancer Causes Control 3: 63-67, 1992.
65. Brown LM, Linet MS, Greenberg RS, et al: Multiple myeloma and family history of cancer among blacks and whites in the U.S. Cancer 85: 2385-2390, 1999. (Pubitemid 29244847)
66. Ogmundsdottir HM, Haraldsdottirm V, Johannesson GM, et al: Familiality of benign and malignant paraproteinemias. A population-based cancer-registry study of multiple myeloma families. Haematologica 90: 66-71, 2005. (Pubitemid 40193755)
67. Lynch HT, Watson P, Tarantolo S, et al: Phenotypic heterogeneity in multiple myeloma families. J Clin Oncol 23: 685-693, 2005. (Pubitemid 46224167)
68. Kristinsson SY, Bjorkholm M, Goldin LR, et al: Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer 125: 2147-2150, 2009.
69. Landgren O, Kristinsson SY, Goldin LR, et al: Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden. Blood 114: 791-795, 2009.
70. Zheng C, Huang DR, Bergenbrant S, et al: Interleukin 6, tumour necrosis factor α, interleukin 1β and interleukin 1 receptor antagonist promoter or coding gene polymorphisms in multiple myeloma. Br J Haematol 109: 39-45, 2000. (Pubitemid 30340577)
71. Lee KM, Baris D, Zhang Y, et al: Common single nucleotide polymorphisms in immunoregulatory genes and multiple myeloma risk among women in Connecticut. Am J Hematol 85: 560-563, 2010.
72. Zheng C, Huang D, Liu L, et al: Interleukin-10 gene promoter polymorphisms in multiple myeloma. Int J Cancer 95: 184-188, 2001.
73. Du J, Yuan Z, Zhang C, et al: Role of the TNF-α promoter polymorphisms for development of multiple myeloma and clinical outcome in thalidomide plus dexamethasone. Leuk Res 34: 1453-1458, 2010.
74. Demeter J, Messer G, Ramisch S, et al: Polymorphism within the second intron of the IL-1 receptor antagonist gene in patients with hematopoietic malignancies. Cytokines Mol Ther 2: 239-242, 1996.
75. Cozen W, Gebregziabher M, Conti DV, et al: Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev 15: 2285-2291, 2006.
76. Duch CR, Figueiredo MS, Ribas C, Almeida MS, Colleoni GW and Bordin JO: Analysis of polymorphism at site -174 G/C of interleukin-6 promoter region in multiple myeloma. Braz J Med Biol Res 40: 265-267, 2007. (Pubitemid 46237859)
77. Abazis-Stamboulieh D, Oikonomou P, Papadoulis N, Panayiotidis P, Vrakidou E and Tsezou A: Association of interleukin-1A, interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms with multiple myeloma. Leuk Lymphoma 48: 2196-2203, 2007. (Pubitemid 350091062)
78. Davies FE, Rollinson SJ, Rawstron AC, et al: High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J Clin Oncol 18: 2843-2851, 2000. (Pubitemid 30620072)
79. Morgan GJ, Adamson PJ, Mensah FK, et al: Haplotypes in the tumour necrosis factor region and myeloma. Br J Haematol 129: 358-365, 2005.
80. Mazur G, Bogunia-Kubik K, Wrobel T, et al: IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett 96: 241-246, 2005. (Pubitemid 39600781)
81. Aladzsity I, Kovacs M, Semsei A, et al: Comparative analysis of IL6 promoter and receptor polymorphisms in myelodysplasia and multiple myeloma. Leuk Res 33: 1570-1573, 2009.
82. Birmann BM, Tamimi RM, Giovannucci E, et al: Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev 18: 282-288, 2009.
83. Kadar K, Kovacs M, Karadi I, et al: Polymorphisms of TNF-alpha and LT-alpha genes in multiple myeloma. Leuk Res 32: 1499-1504, 2008.
84. Pratt G, Fenton JA, Allsup D, et al: A polymorphism in the 3′ UTR of IRF4 linked to susceptibility and pathogenesis in chronic lymphocytic leukaemia and Hodgkin lymphoma has limited impact in multiple myeloma. Br J Haematol 150: 371-373, 2010.
85. Vangsted AJ, Klausen TW, Ruminski W, et al: The polymorphism IL-1β T-31C is associated with a longer overall survival in patients with multiple myeloma undergoing auto-SCT. Bone Marrow Transplant 43: 539-545, 2009.
86. Brown EE, Lan Q, Zheng T, et al: Common variants in genes that mediate immunity and risk of multiple myeloma. Int J Cancer 120: 2715-2722, 2007. (Pubitemid 46651296)
87. Bommert K, Bargou RC and Stuhmer T: Signalling and survival pathways in multiple myeloma. Eur J Cancer 42: 1574-1580, 2006. (Pubitemid 44118772)
88. Podar K, Chauhan D and Anderson KC: Bone marrow micro-environment and the identification of new targets for myeloma therapy. Leukemia 23: 10-24, 2009.
89. Li ZW, Chen H, Campbell RA, Bonavida B and Berenson JR: NF-kappaB in the pathogenesis and treatment of multiple myeloma. Curr Opin Hematol 15: 391-399, 2008.
90. Chng WJ, Glebov O, Bergsagel PL and Kuehl WM: Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 20: 571-596, 2007. (Pubitemid 350215376)
91. Parker KM, Ma MH, Manyak S, et al: Identification of polymorphisms of the IκBα gene associated with an increased risk of multiple myeloma. Cancer Genet Cytogenet 137: 43-48, 2002.
92. Spink CF, Gray LC, Davies FE, Morgan GJ and Bidwell JL: Haplotypic structure across the IκBα gene (NFKBIA) and association with multiple myeloma. Cancer Lett 246: 92-99, 2007. (Pubitemid 44959379)
93. Du J, Huo J, Shi J, et al: Polymorphisms of NF-κB family genes are associated with development of multiple myeloma and treatment outcome in patients undergoing bortezomib-based regimens. Haematologica 96: 729-737, 2011.
94. Purdue MP, Lan Q, Menashe I, et al: Variation in innate immunity genes and risk of multiple myeloma. Hematol Oncol 29: 42-46, 2011.
95. Hosgood HD III, Baris D, Zhang Y, et al: Genetic variation in cell cycle and apoptosis related genes and multiple myeloma risk. Leuk Res 33: 1609-1614, 2009.
96. Ostrovsky O, Korostishevsky M, Levite I, et al: Association of heparanase gene (HPSE) single nucleotide polymorphisms with hematological malignancies. Leukemia 21: 2296-2303, 2007. (Pubitemid 350011702)
97. Pemberton NC, Paneesha S, Hiller L, et al: The SDF-1 G > A polymorphism at position 801 plays no role in multiple myeloma but may contribute to an inferior cause-specific survival in chronic lymphocytic leukemia. Leuk Lymphoma 47: 1239-1244, 2006.
98. Hayden PJ, Tewari P, Morris DW, et al: Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma. Hum Mol Genet 16: 3117-3127, 2007. (Pubitemid 350131330)
99. Roddam PL, Rollinson S, O'Driscoll M, Jeggo PA, Jack A and Morgan GJ: Genetic variants of NHEJ DNA ligase IV can affect the risk of developing multiple myeloma, a tumour characterised by aberrant class switch recombination. J Med Genet 39: 900-905, 2002. (Pubitemid 36009151)
100. Vangsted A, Gimsing P, Klausen TW, et al: Polymorphisms in the genes ERCC2, XRCC3 and CD3EAP influence treatment outcome in multiple myeloma patients undergoing autologous bone marrow transplantation. Int J Cancer 120: 1036-1045, 2007. (Pubitemid 46214303)
101. Hosgood HD III, Baris D, Zhang Y, et al: Caspase polymorphisms and genetic susceptibility to multiple myeloma. Hematol Oncol 26: 148-151, 2008.
102. Ortega MM, Honma HN, Zambon L, et al: GSTM1 and codon 72 P53 polymorphism in multiple myeloma. Ann Hematol 86: 815-819, 2007. (Pubitemid 47497100)
103. Maggini V, Buda G, Galimberti S, et al: Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk. Leuk Res 32: 988-990, 2008. (Pubitemid 351389549)
104. Ortega MM, Nascimento H, Melo MB, Teori MT, Costa FF and Lima CS: Polymorphisms of glutathione S-transferase mu1 (GSTM1) and theta1 (GSTT1) genes in multiple myeloma. Acta Haematol 109: 108-109, 2003. (Pubitemid 36302355)
105. Lincz LF, Kerridge I, Scorgie FE, Bailey M, Enno A and Spencer A: Xenobiotic gene polymorphisms and susceptibility to multiple myeloma. Haematologica 89: 628-629, 2004. (Pubitemid 38691261)
106. Lincz LF, Scorgie FE, Robertson R and Enno A: Genetic variations in benzene metabolism and susceptibility to multiple myeloma. Leuk Res 31: 759-763, 2007. (Pubitemid 46855888)
107. Gold LS, De Roos AJ, Brown EE, et al: Associations of common variants in genes involved in metabolism and response to exogenous chemicals with risk of multiple myeloma. Cancer Epidemiol 33: 276-280, 2009.
108. Pereira TV, Rudnicki M, Pereira AC, Pombo-de-Oliveira MS and Franco RF: 5,10-Methylenetetrahydrofolate reductase polymorphisms and acute lymphoblastic leukemia risk: a meta-analysis. Cancer Epidemiol Biomarkers Prev 15: 1956-1963, 2006. (Pubitemid 44664274)
109. Webb EL, Rudd MF, Sellick GS, et al: Search for low penetrance alleles for colorectal cancer through a scan of 1467 non-synony- mous SNPs in 2575 cases and 2707 controls with validation by kin-cohort analysis of 14704 first-degree relatives. Hum Mol Genet 15: 3263-3271, 2006. (Pubitemid 44605505)
110. Gonzalez Ordonez AJ, Fernandez Carreira JM, Fernandez Alvarez CR, et al: Normal frequencies of the C677T genotypes on the methylenetetrahydrofolate reductase (MTHFR) gene among lymphoproliferative disorders but not in multiple myeloma. Leuk Lymphoma 39: 607-612, 2000. (Pubitemid 32162399)
111. Yanamandra K, Bocchini JA Jr and Thurmon TF: Methylenetetrahydrofolate reductase 677CC normal genotype may protect against multiple myeloma. Br J Haematol 120: 1094-1095; author reply 1095-1096, 2003.
112. Lima CS, Ortega MM, Ozelo MC, et al: Polymorphisms of methylenetetrahydrofolate reductase (MTHFR), methionine synthase (MTR), methionine synthase reductase (MTRR), and thymidylate synthase (TYMS) in multiple myeloma risk. Leuk Res 32: 401-405, 2008. (Pubitemid 351295908)
113. Chiusolo P, Farina G, Putzulu R, et al: Analysis of MTHFR polymorphisms and P16 methylation and their correlation with clinical-biological features of multiple myeloma. Ann Hematol 85: 474-477, 2006. (Pubitemid 44283115)
114. Kim HN, Kim YK, Lee IK, et al: Polymorphisms involved in the folate metabolizing pathway and risk of multiple myeloma. Am J Hematol 82: 798-801, 2007.
115. Gonzalez-Fraile MI, Garcia-Sanz R, Mateos MV, et al: Methylenetetrahydrofolate reductase genotype does not play a role in multiple myeloma pathogenesis. Br J Haematol 117: 890-892, 2002. (Pubitemid 34639253)
116. Hatzimichael E, Dasoula A, Benetatos L, et al: Study of specific genetic and epigenetic variables in multiple myeloma. Leuk Lymphoma 51: 2270-2274, 2010.
117. Lincz LF, Scorgie FE, Kerridge I, Potts R, Spencer A and Enno A: Methionine synthase genetic polymorphism MS A2756G alters susceptibility to follicular but not diffuse large B-cell non-Hodgkin's lymphoma or multiple myeloma. Br J Haematol 120: 1051-1054, 2003. (Pubitemid 36411565)
118. Zintzaras E, Giannouli S, Rodopoulou P and Voulgarelis M: The role of MTHFR gene in multiple myeloma. J Hum Genet 53: 499-507, 2008.
119. Jamroziak K, Balcerczak E, Calka K, et al: Polymorphisms and haplotypes in the multidrug resistance 1 gene (MDR1/ABCB1) and risk of multiple myeloma. Leuk Res 33: 332-335, 2009.
120. Kang SH, Kim TY, Kim HY, et al: Protective role of CYP1A1*2A in the development of multiple myeloma. Acta Haematol 119: 60-64, 2008. (Pubitemid 351363862)
121. Neben K, Mytilineos J, Moehler TM, et al: Polymorphisms of the tumor necrosis factor-α gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood 100: 2263-2265, 2002. (Pubitemid 35001268)
122. Dasgupta RK, Adamson PJ, Davies FE, et al: Polymorphic variation in GSTP1 modulates outcome following therapy for multiple myeloma. Blood 102: 2345-2350, 2003. (Pubitemid 37193568)
123. Dumontet C, Landi S, Reiman T, et al: Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan. Bone Marrow Transplant 45: 1316-1324, 2010.
124. Maggini V, Buda G, Galimberti S, et al: Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms. Leuk Res 32: 49-53, 2008. (Pubitemid 350100838)
125. Maggini V, Buda G, Galimberti S, et al: Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation. Leukemia 21: 176-178, 2007. (Pubitemid 44921852)
126. Schilthuizen C, Broyl A, van der Holt B, De Knegt Y, Lokhorst H and Sonneveld P: Influence of genetic polymorphisms in CYP3A4, CYP3A5, GSTP1, GSTM1, GSTT1 and MDR1 genes on survival and therapy-related toxicity in multiple myeloma. Haematologica 92: 277-278, 2007. (Pubitemid 46852440)
127. Maggini V, Buda G, Martino A, et al: MDR1 diplotypes as prognostic markers in multiple myeloma. Pharmacogenet Genomics 18: 383-389, 2008. (Pubitemid 351535939)
128. Buda G, Ricci D, Huang CC, et al: Polymorphisms in the multiple drug resistance protein 1 and in P-glycoprotein 1 are associated with time to event outcomes in patients with advanced multiple myeloma treated with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 89: 1133-1140, 2010.
129. Buda G, Martino A, Maggini V, et al: MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma. Acta Haematol 122: 42-45, 2009.
130. Buda G, Maggini V, Galimberti S, et al: MDR1 polymorphism influences the outcome of multiple myeloma patients. Br J Haematol 137: 454-456, 2007. (Pubitemid 46698294)
131. Vangsted AJ, Soeby K, Klausen TW, et al: No influence of the polymorphisms CYP2C19 and CYP2D6 on the efficacy of cyclophosphamide, thalidomide, and bortezomib in patients with Multiple Myeloma. BMC Cancer 10: 404, 2010.
132. Li Y, Hou J, Jiang H, et al: Polymorphisms of CYP2C19 gene are associated with the efficacy of thalidomide based regimens in multiple myeloma. Haematologica 92: 1246-1249, 2007. (Pubitemid 350144185)
133. Vangsted AJ, Klausen TW, Gimsing P, et al: A polymorphism in NFKB1 is associated with improved effect of interferon-α maintenance treatment of patients with multiple myeloma after high-dose treatment with stem cell support. Haematologica 94: 1274-1281, 2009.
134. Vangsted AJ, Klausen TW, Abildgaard N, et al: Single nucleotide polymorphisms in the promoter region of the IL1B gene influence outcome in multiple myeloma patients treated with high-dose chemotherapy independently of relapse treatment with thalidomide and bortezomib. Ann Hematol 90: 1173-1181, 2011.
135. Bachmann HS, Novotny J, Sixt S, et al: The G-Allele of the PSMA6-8C>G polymorphism is associated with poor outcome in multiple myeloma independently of circulating proteasome serum levels. Eur J Haematol 85: 108-113, 2010.
136. Richardson PG: Towards a better understanding of treatment-related peripheral neuropathy in multiple myeloma. Lancet Oncol 11: 1014-1016, 2010.
137. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB and Prince HM: Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24: 4507-4514, 2006. (Pubitemid 46630990)
138. Richardson PG, Weller E, Jagannath S, et al: Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 27: 5713-5719, 2009.
139. Broyl A, Corthals SL, Jongen JL, et al: Mechanisms of peri- pheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 11: 1057-1065, 2010.
140. Johnson DC, Corthals SL, Walker BA, et al: Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 29: 797-804, 2011.
141. Johnson DC, Corthals S, Ramos C, et al: Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood 112: 4924-4934, 2008.
142. Van den Wyngaert T, Huizing MT and Vermorken JB: Osteonecrosis of the jaw related to the use of bisphosphonates. Curr Opin Oncol 19: 315-322, 2007. (Pubitemid 46883519)
143. Sarasquete ME, Garcia-Sanz R, Marin L, et al: Bisphosphonate-related osteonecrosis of the jaw is associated with polymorphisms of the cytochrome P450 CYP2C8 in multiple myeloma: a genome-wide single nucleotide polymorphism analysis. Blood 112: 2709-2712, 2008.
144. Song H, Ramus SJ, Tyrer J, et al: A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet 41: 996-1000, 2009.
145. Ahmed S, Thomas G, Ghoussaini M, et al: Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet 41: 585-590, 2009.
146. Lindstrom S, Schumacher F, Siddiq A, et al: Characterizing associations and SNP-environment interactions for GWAS-identified prostate cancer risk markers - results from BPC3. PLoS One 6: e17142, 2011.
147. Sherborne AL, Hemminki K, Kumar R, et al: Rationale for an international consortium to study inherited genetic susceptibility to childhood acute lymphoblastic leukemia. Haematologica 96: 1049-1054, 2011.
148. Tomlinson IP, Dunlop M, Campbell H, et al: COGENT (COlorectal cancer GENeTics): an international consortium to study the role of polymorphic variation on the risk of colorectal cancer. Br J Cancer 102: 447-454, 2009.